Autopsy report · NCT05077423

A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

“Study terminated due to business priorities”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 6 months before it stopped.
• 3 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Y-mAbs Therapeutics

Sponsor type

Industry

Conditions

AML, Childhood

Interventions

CD33*CD3 BsAb

Participants

3

Sites

13

Countries

United States

Trials that died the same way

• A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants
  “Study terminated due to business decision” (92% match in meaning)
• The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B
  “Study terminated due to business and strategic decision” (92% match in meaning)
• Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours
  “Study terminated for business reasons” (91% match in meaning)
• TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
  “Study terminated for strategic business reasons” (90% match in meaning)
• Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
  “The study was terminated due to a business decision.” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.